EGFR and non-small cell lung carcinoma: In this network meta-analysis (NMA) of randomized controlled trials, we aimed to provide a well-designed comparative synthesis of the relative efficacy and safety of all combination treatments involving third-generation EGFR-TKIs in patients with advanced EGFR-mutated NSCLC as first-line therapy.